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The thiuram disulfide, disulfiram (Antabuse®, Figure 1) is a 
well-established drug used in the treatment of alcoholism 
(aversion therapy) by virtue of its aldehyde dehydrogenase 
(ALDH) inhibitory activity.
1
 Previous studies within our group 
have identified disulfiram as a zinc-binding inhibitor of the E3 
ubiquitin ligase enzyme, BCA2 (Breast Cancer Associated 
protein 2),
2
 a clinically over-expressed protein in breast cancer 
patients and a target for cancer drug discovery.
3
 The interesting 
and multi-faceted anticancer activity of disulfiram, coupled with 
its favourable clinical toxicological and safety profile, has led to 
the initiation of several cancer clinical trials using this agent.
4
  
 
Figure 1. Chemical structures of disulfiram and 
carbamo(dithioperoxo)thioates as potential metabolites. 
 
The in vivo pharmacokinetic profile of disulfiram in patients is 
complex and is incompletely understood. The initial cleavage of 
the weak disulfide bond to form the corresponding 
diethyldithiocarbamate anion (known as ditiocarb) is well 
established. It has been postulated that the complex of ditiocarb 
with copper(II) ions (CuEt) formed in the blood is likely to be 
responsible for the anticancer activity of disulfiram.
5
 An 
alternative reported pharmacokinetic pathway involves the 
formation of carbamo(dithioperoxo)thioates (mixed disulfides 
derived from disulfiram, Figure 1) following initial formation of 
ditiocarb. Notably carbamo(dithioperoxo)thioates have been 
reported as inhibitors of human mitochondrial
6
 and sheep liver
7
 
ALDH, the therapeutic target on which clinical approval of 
disulfiram is based. 
During previous work investigating the BCA2-inhibitory 
activity of disulfiram analogues, we synthesized a small series of 
carbamo(dithioperoxo)thioates by heating a mixture of disulfiram 
(or related piperidinyl or pyrrolidinyl analogues) with alkyl thiols 
in ethanol under reflux (Scheme 1).
2
 This procedure led to the 
formation of the required carbamo(dithioperoxo)thioate products 
in low yields (9-25%) following extensive column 
chromatography, alongside a number of mixed disulfide-based 
by-products. 
 
Scheme 1. Previously reported synthesis of carbamo(dithioperoxo)thioates by 
reaction of disulfiram analogues with alkyl thiols. 
 
 Testing of new disulfiram analogues and the structurally 
related carbamo(dithioperoxo)thioates in human breast cancer 
cell lines with differing levels of expression of BCA2, including 
isogenic cell lines MDA-MB-231 (BCA
low/-
) and MDA-MB-
231/ER (BCA2
+
), revealed interesting results.
2
 Of particular note 
were the carbamo(dithioperoxo)thioates derived from reaction of 
disulfiram with hexanethiol or 2-mercaptoethanol (Figure 1; R = 
n-hexyl, HOCH2CH2). Both of these analogues exhibited sub-
micromolar IC50 activity selectively in BCA2-expressing breast 
cancer cell lines, whilst lacking the ALDH-inhibitory activity 
characteristic of the parent compound disulfiram. 
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A new, simple, one-step synthetic route to carbamo(dithioperoxo)thioates from commercially 
available starting materials is described. The key step of this new synthetic approach involves 
the tetrabromomethane-promoted reaction between secondary amines, carbon disulfide and alkyl 
thiols under basic conditions at room temperature. New compounds from this series selected for 
anticancer screening showed selective sub-micromolar activity within BCA2-expressing human 
breast cancer cell lines. 
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Given the biological relevance of the 
carbamo(dithioperoxo)thioates in the context of anticancer drug 
discovery, and the difficulties in obtaining pure products through 
the previously described mixed disulfide method,
2
 we required a 
new synthetic protocol for reliable and high yielding access to 
this class of compound. In this paper, we describe a simple, one-
step protocol for the synthesis of a range of substituted 
carbamo(dithioperoxo)thioates under mild conditions. Our new 
method is based on the procedure developed by Liang and co-
workers, using tetrabromomethane (CBr4) to promote the 
synthesis of thioureas and thiuram disulfides via reaction of 
amines with carbon disulfide.
8 
The use of carbon tetrabromide to 
promote the reaction of dithioic acids or thiols with active 
methylene compounds to produce dithiocarbamates, xanthates, 
dithioesters and thioethers has also been previously reported.
9
 
Critical to these studies was the proposed generation of a sulfenyl 
bromide intermediate. 
We now report the extension of the above studies to the 
synthesis of carbamo(dithioperoxo)thioates. Initially, we 
optimized the reaction conditions based on the reaction between 
diethylamine, carbon disulfide, 2-mercaptoethanol or 
hexanethiol, and triethylamine as the base, to investigate the 
formation of the previously described lead compounds shown in 
Figure 1 (R = n-hexyl, HOCH2CH2). As a first adaptation of the 
previously reported method,
8
 the use of equimolar quantities of 
reagents without base in DMF as the solvent at room temperature 
gave very low yields of product. Reactions of equimolar 
quantities of these reagents promoted by triethylamine in 
dichloromethane in the absence of CBr4 did not lead to the 
desired carbamo(dithioperoxo)thioate products. Adding one 
equivalent of CBr4 in dichloromethane produced the products in 
48% and 38% yields, respectively. Surprisingly, the use of two 
equivalents of alkyl thiol did not lead to the desired products, 
instead yielding the corresponding dithiocarbamates (confirmed 
by mass spectrometry and NMR) as by-products. Finally, it was 
found that the use of two equivalents of CBr4 gave the products in 
good yields (85% and 58%, respectively) under mild conditions 
(room temperature, 2 h reaction time). This optimized procedure 
was subsequently adopted for the synthesis of new 
carbamo(dithioperoxo)thioate analogues. 
Following mixing of equimolar quantities of secondary amine 
(1a-f) and alkyl thiol (2a-d) in anhydrous dichloromethane, the 
mixture was cooled in an ice bath. Carbon disulfide (1 equiv) was 
then added dropwise, followed by slow addition of triethylamine 
(1.1 equiv). After a further five minutes, a solution of CBr4 (2 
equiv) in dichloromethane was added, followed by stirring at 
room temperature for two hours. Product work-up and 
purification by column chromatography gave 
carbamo(dithioperoxo)thioates 3a-x (>60% yield in most cases) 
(Scheme 2). 
Scheme 2. Optimized synthesis of carbamo(dithioperoxo)thioate analogues 
3a-x. 
The identity of the carbamo(dithioperoxo)thioate products was 
confirmed by NMR spectroscopy and mass spectrometry. 
Compound purity following column chromatography was further 
verified by either microanalysis (duplicate % CHN) or accurate 
mass determination (see Supplementary data). Good yields were 
obtained for the majority of products, however, in the case of 
compounds 3q and 3u (derived from 2-mercaptoethanol and 
morpholine or N-methylpiperazine), lower yields (25% and 30% 
respectively) were obtained. Overall, our results are consistent 
with the formation of an intermediate sulfenyl bromide, as was 
postulated in the previous related studies.
8,9
  
As a continuation of our previously published studies on the 
anticancer properties of these new disulfiram-derived 
molecules,
1,2
 we carried out a preliminary in vitro evaluation 
across human breast cancer cell lines where BCA2 expression 
status was known (72 h compound treatment time). The mean 
IC50 values (triplicate analysis) for compounds 3i, 3k, 3o, 3s and 
3w (derived from a variety of secondary amines) in human breast 
cancer cell lines MCF-7 (BCA2-positive), MDA-MB-231 
(BCA2-negative) and MCF-10A (non-cancerous control) were 
determined. The results presented in Table 1 indicate selective 
sub-micromolar IC50 activity selectively within MCF-7 cells, 
consistent with previously synthesized analogues of this broad 
class.
2
 One analogue (3o) possessed a biphasic dose-response 
profile, a phenomenon previously observed within our group for 
disulfiram.
1
  
In conclusion, we have developed and optimized a new one-
pot synthetic route to a range of potential anticancer 
carbamo(dithioperoxo)thioates in high yields, including the 
previous BCA2-inhibitory compounds from our previous study 
(compounds 3a and 3c in 58% and 85% yields, respectively). 
Further studies of the anticancer properties of this new series are 
ongoing. 
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C o mp o un d  MC F-7  MDA - MB -
2 3 1  
MC F-
1 0 A 
3 i  0 . 5  > 1 0  > 1 0  
3 k  0 . 9  > 1 0  > 1 0  
3 o  0 . 6
a
 > 1 0  > 1 0  
3 s  1  1 0  > 1 0  
3 w  0 . 9  > 1 0  > 1 0  
The results are the mean values from three independent experiments; 
a
indicates the first IC50 value of a biphasic dose-response profile. 
Table 1. IC50 values (M) in human breast cancer cell lines 
MCF-7 (BCA2 +ve), MDA-MB-231 (BCA2 –ve) and MCF-
10A (control proliferative cell line). 
 
 
Figure 1. Chemical structures of disulfiram and 
carbamo(dithioperoxo)thioates as potential metabolites. 
 
 
Scheme 1. Previously reported synthesis of 
carbamo(dithioperoxo)thioates by reaction of disulfiram 
analogues with alkyl thiols. 
 
Scheme 2. Optimized synthesis of 
carbamo(dithioperoxo)thioate analogues 3a-x. 
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